Effect of recombinant endostatin on Treg, CD8+T cells,TSGF in peripheral blood of patients with advance desophageal gastric junction adenocarcinoma and clinical observation
- VernacularTitle:重组血管内皮抑素对晚期食管胃交接部腺癌患者外周血Treg、CD8＋T细胞、TSGF影响及疗效观察
- Author:
Yu GUO
;
Zhili REN
;
Ruixin ZAHNG
- Publication Type:Journal Article
- Keywords:
recombinant endostatin;
advanced adenocarcinoma of esophagogastric junction;
Treg;
CD8 +T cells;
tumor specific growth factor;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(8):158-160
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyse the effect of recombinant endostatin on Treg, CD8 +T cells, tumor specific growth factor (TSGF) in peripheral blood of patients with advanced esophageal gastric junction adenocarcinoma and clinical efficacy observation.Methods 52 patients who were diagnosed with acute cerebral infarction in our hospital were collected.All patients were randomly divided into experimental group and control group, 26 cases in each group.The control group was given OLF chemotherapy, the experimental group was treated with OLF chemotherapy regimen combined with recombinant endostatin.21 days was 1 cycle, a total of 4 cycles.After treatment, the levels of Treg, CD8 +T cells, serum TSGF and clinical efficacy were detected in all patients.ResuIts After treatment, compared with control group,the peripheral blood Treg was significantly lower in the experimental group (P<0.05); the peripheral blood CD8 +T cells level in the experimental group was significantly higher (P<0.05);the serum TSGF level in the experimental group was significantly lower ( P<0.05 ); the effective of patients in the experimental group was higher ( P<0.05 ) . ConcIusion Recombinant endostatin can significantly reduce the levels of Treg and serum TSGF in patients with advanced esophageal gastric junction adenocarcinoma, improve the level of CD8 +T cells, and improve the efficiency of treatment, have guiding significance to clinical.
